Which German Claims Data Route Is Right for Pharma? FDZ vs. Commercial Providers
From MEDDDICAL podcasts
Show by MEDDDICAL
Ninety percent of Germans generate health claims data, yet pharma researchers face a maze of access routes. One government-run gateway promises rigor, another commercial path promises speed - so which one actually fits your research question? Learn more at https://medddical.com/health-insurance-datasets/german-health-data-providers-claims-data-gdng/
More episodes of MEDDDICAL podcasts
More episodes
- Half the Story Was Always Missing: What Real-World Patient Data Changes Now
- Why Are Pharma Companies Investing in Insurance Claims Data & Real-World Data?
- Phenotype Validation in Real-World Data: Why It Makes or Breaks Your Study
- Longitudinal RWE in Pharma: What Makes a Dataset Fit for Purpose?
- What It Takes to Build Predictive Models That Actually Work
- Real-World Pharma Data: How It's Reshaping Modern Drug Development
- AI Synthetic Health Data: What Works for Pharma & What Doesn't
- How AI-Powered RWE Is Cutting Drug Costs & Accelerating Development
- Claims Data or EHR? How to Choose the Right Source for Your Study
- AI In RWE: How Choosing The Wrong Dataset Can Result In Clinical Disasters
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.